Yonsa, New Formulation of Abiraterone Acetate, Approved for Advanced Castration-resistant Prostate Cancer

Yonsa, New Formulation of Abiraterone Acetate, Approved for Advanced Castration-resistant Prostate Cancer
Yonsa was recently approved by the U.S. Food and Drug Administration, in combination with methylprednisolone, for the treatment of metastatic castration-resistant prostate cancer. The announcement was made by Sun Pharma and Churchill Pharmaceuticals. Yonsa is a new formulation of abiraterone acetate, an already approved hormone therapy for men with advanced, castration-resistant prostate cancer, sold under the brand name Zytiga (Janssen Biotech). The new medication is a result of a partnership between Sun Pharma and Churchill. It uses a proprietary technology to create a smaller particle size, or micronized, formulation of abiraterone acetate tablets that improves i
Subscribe or to access all post and page content.